Brussels, Belgium, December 15, 2015

Merodis, a corporate finance consulting firm, is proud to announce it successfully assisted Sophia Genetics with its CHF 15m Series C financing which was led by Marc Coucke’s investment firm Alychlo, alongside the existing shareholders.

The proceeds will be used amongst others to further accelerate an already impressive market roll-out of Sophia Genetics’ offering, hence further boosting its projected growth and market dominance within its specific domain in Europe.

Sophia Genetics (www.sophiagenetics.com) is the global leader in Data Driven Medicine (DDM) hosting the world’s largest clinical genomics community for molecular diagnosis through its platform, Sophia DDM™, hereby placing Europe ahead of the US in precision medicine. The company currently supports over 110 institutions across 20 countries, and is positioning as the largest global market player for interpreting pseudonymised genomics data and promoting experts’ knowledge sharing for genomic variants clinical interpretation.

For more information, please contact:

Dirk Marckx
dma@merodis.com , +32 495 38 17 81
Thierry Hazevoets
tha@merodis.com, +32 495 58 68 98